bioAffinity's noninvasive lung cancer test to be added to U.S. Federal Supply Schedule

bioAffinity Technologies (NASDAQ:BIAF), a pioneering biotechnology firm specializing in noninvasive early-stage cancer diagnostics, has announced that its innovative lung cancer detection test, CyPath® Lung, will soon be accessible through the U.S. Federal Supply Schedule.

This inclusion will streamline the availability of CyPath® Lung to the Veterans Health Administration (VHA) and the Military Health System, enhancing early lung cancer detection efforts among veterans.

The VHA, an integral component of the U.S. Department of Veterans Affairs, operates the nation's largest integrated health care system.

It provides comprehensive care to approximately 9.1 million veterans annually through 1,380 healthcare facilities, which include 170 medical centers and 1,193 outpatient clinics of varying complexities.

With lung cancer being a significant health concern among veterans—approximately 8,000 are diagnosed each year—the availability of CyPath® Lung on the Federal Supply Schedule represents a significant advancement in the efforts to combat this deadly disease through early detection and treatment.